Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Angiotensin II Type 2 Receptor Blockers
/ therapeutic use
Angiotensin Receptor Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Angiotensins
/ therapeutic use
Antihypertensive Agents
Czech Republic
/ epidemiology
Heart Failure
/ drug therapy
Humans
Losartan
/ therapeutic use
Neprilysin
/ therapeutic use
Perindopril
/ therapeutic use
Ramipril
/ therapeutic use
Retrospective Studies
Telmisartan
/ therapeutic use
Valsartan
/ therapeutic use
Czech Republic
European Union
angiotensin-II-receptor antagonists
angiotensin-converting enzyme (ACE) inhibitors
heart failure
sacubitril/valsartan
Journal
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
03
01
2021
accepted:
28
05
2021
pubmed:
8
6
2021
medline:
21
9
2022
entrez:
7
6
2021
Statut:
ppublish
Résumé
Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II-receptor antagonists (ARB) and angiotensin receptor blocker/neprilysin inhibitor (ARNI) use. ACEi and ARBs were generally used in 87.6% of all HF patients in 2012 (n=154 627); 84.5% in 2013 (n=170 861); 83.5% in 2014 (n=186 963); 81.6% in 2015 (n=198 844); 80.1% in 2016 (n=205 793); 78.0% in 2017 (n=212 152) and in 76.7% in 2018 (n=219 235). In a sub-analysis of patients with a medical procedure and/or examination using an I50.x ICD code accounted for in the given year, ACEi and ARBs were generally used in 99.3% in 2012 (n=63 250); 96% in 2013 (n=62 241); 95.2% in 2014 (n=64 414); 93.3% in 2015 (n=65 217); 91.8% in 2016 (n=65 236); 90.1% in 2017 (n=65 761) and in 88.6% in 2018 (n=66 332). In 2018, the majority of patients with HF were prescribed ramipril (n=49 909; 17.5%) and perindopril (n=44 332; 15.5%). The mostly prescribed ARBs in 2018 were telmisartan (n=18 669; 6.5%); losartan (n=13 935; 4.9%) and valsartan (n=4 849; 1.7%). In 24.5% of cases, ACEIs and ARBs were prescribed in a fixed combination with another drug. ARNI became gradually more prescribed from 2018 (n=9 659 in November 2020). In an analysis of ACEIs, ARBs and ARNIs utilization in all patients treated for heart failure in the given year in the whole country, we found a comparable rate of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Ramipril and perindopril remained the mostly prescribed ACEIs and telmisartan became the mostly prescribed ARB. Since 2018, ARNIs began to be widely prescribed.
Substances chimiques
Angiotensin II Type 2 Receptor Blockers
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensins
0
Antihypertensive Agents
0
Valsartan
80M03YXJ7I
Neprilysin
EC 3.4.24.11
Losartan
JMS50MPO89
Ramipril
L35JN3I7SJ
Telmisartan
U5SYW473RQ
Perindopril
Y5GMK36KGY
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
322-327Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-2200.
pubmed: 27206819
doi: 10.1093/eurheartj/ehw128
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993-1004.
doi: 10.1056/NEJMoa1409077
Spinar J, Spinarova L, Malek F, Ludka O, Krejci J, Ostadal P, Vondrakova D, Labr K, Spinarova M, Pavkova Goldbergova M, Benesova K, Jarkovsky J, Parenica J. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry. PLoS One 2019;14(3):e0214363.
pubmed: 30913251
doi: 10.1371/journal.pone.0214363
Spinar J, Jarkovsky J, Spinarova L, Mebazaa A, Gayat E, Vitovec J, Linhart A, Widimsky P, Miklik R, Zeman K, Belohlavek J, Malek F, Felsoci M, Kettner J, Ostadal P, Cihalik C, Vaclavik J, Taborsky M, Dusek L, Littnerova S, Parenica J. AHEAD score-Long-term risk classification in acute heart failure. Int J Cardiol 2016;202:21-6.
doi: 10.1016/j.ijcard.2015.08.187
Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, Dahlström U. Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. Eur J Heart Fail 2017;19(9):1107-116.
doi: 10.1002/ejhf.762
Omersa D, Farkas J, Erzen I, Lainscak M. National trends in heart failure hospitalization rates in Slovenia 2004-2012. Eur J Heart Fail 2016;18(11):1321-28.
doi: 10.1002/ejhf.617
Spinar J, Hradec J, Spinarova L, Vitovec J. Souhrn Doporučených postupů ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Cor et Vasa 2016, 58.5: e530-e568. (In Czech)
doi: 10.1016/j.crvasa.2016.09.004
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-56.
doi: 10.1001/jama.273.18.1450
Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-76.
doi: 10.1016/S0140-6736(03)14284-5
Spinar J, Vitovec J, Spinarova L. Pharmacotherapy of chronic heart failure after the first decade of 21st century. Vnitrni lekarstvi 2011;57(11):959-65. (In Czech)
pubmed: 22165704
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19(12):1574-85.
doi: 10.1002/ejhf.813
Spinar J, Vitovec J, Spinarova L. Heart Failure with Preserved Ejection Fraction. Vnitřní lékařství 2016;62(7-8):646-51. (In Czech)
pubmed: 27627092
Spinarova L, Spinar J, Vitovec J. Pharmacotherapy following myocardial infarction. Vnitřní lékařství 2011;57(11):966-70. (In Czech)
pubmed: 22165705
Spinar J, Vitovec J, Spinarova L. FARIM-FARmakoterapie po Infarktu Myokardu (Post-Myocardial Infarction Pharmacotherapy Study). Vnitrni lekarstvi 2011;57(9):778-84.
pubmed: 21957774
Vitovec J, Spinarova L, Spinar J. Sekundární prevence po infarktu myokardu-režimové a farmakologické postupy. Interní medicína pro praxi 2011;13(5):202-4. (In Czech)